S. Karger AG

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Rosenberg
    Rosenberg
  3. Feldman
    Feldman
  4. Iyer
    Iyer
  5. Scher
    Scher
  6. Abida
    Abida
  7. Bajorin
    Bajorin
  8. Bosl
    Bosl
  9. Busam
    Busam
  10. Chen
    Chen

Groups

  1. Department of Medicine (35)
  2. Genitourinary Oncology Service (35)
  3. Solid Tumor Oncology Division (35)
  4. Survivorship Research (2)
  5. Breast Medicine Service (1)
  6. Center for Hematologic Malignancies (1)
  7. Department of Pathology and Laboratory Medicine (1)
  8. Dermatology Service (1)
  9. Dermatology (1)
  10. Division of Subspecialty Medicine (1)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (6)
  3. Book Section (1)
Groups
  1. Department of Medicine (35)
  2. Genitourinary Oncology Service (35)
  3. Solid Tumor Oncology Division (35)
  4. Survivorship Research (2)
  5. Breast Medicine Service (1)
  6. Center for Hematologic Malignancies (1)

More Groups

People
  1. Robert Motzer (23)
  2. Jonathan Rosenberg (5)
  3. Darren Feldman (2)
  4. Dean Bajorin (2)
  5. Gopakumar Iyer (2)
  6. Howard Scher (2)

More People

Years
  1. 2022 (2)
  2. 2021 (4)
  3. 2020 (6)
  4. 2019 (3)
  5. 2018 (7)
  6. 2017 (2)

More Years

Publications
  1. Oncology Research and Treatment (27)
  2. Oncology (3)
  3. Onkologie (2)
  4. Basic Research in Urological Oncology (1)
  5. Case Reports in Oncology (1)
  6. Urologia Internationalis (1)

Results (35)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Checkmate 214 post hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma (ARCC) with sarcomatoid features (SRCC)
    Meeting Abstract

    Grimm, M. O.; McDermott, D. F.; Choueiri, T. K.; Motzer, R. J.; Frontera, O. A.; George, S.; Powles, T.; Donskov, F.; Harrison, M. R.; Rodriguez-Cid, J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Association between depth of response (DepOR) and overall survival (OS): Exploratory analysis of nivolumab plus ipilimumab (N plus I) vs sunitinib (S) in patients with previously untreated advanced renal cell carcinoma (ARCC) in Checkmate 214
    Meeting Abstract

    Gruenwald, V.; Choueiri, T. K.; Rini, B. I.; Powles, T.; George, S.; Grimm, M. O.; McHenry, M. B.; Maurer, M.; Motzer, R. J.; Hammers, H. J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC)
    Meeting Abstract

    von Amsberg, G.; Balar, A. V.; Dreicer, R.; Loriot, Y.; Perez-Gracia, J. L.; Hoffman-Censits, J. H.; Petrylak, D. P.; van der Heijden, M. S.; Shen, X.; Ding, B.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • CheckMate 214 patients who discontinued first-line nivolumab + ipilimumab or sunitinib due to treatment-related adverse events
    Meeting Abstract

    Grünwald, V.; Tannir, N. M.; Motzer, R. J.; Plimack, E. R.; McDermott, D. F.; Barthélémy, P.; Porta, C.; George, S.; Powles, T.; Donskov, F.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Grüllich, C.; Rini, B. I.; Huseni, M.; Atkins, M.; McDermott, D.; Powles, T.; Escudier, B.; Banchereau, R.; Liu, L. F.; Leng, N.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Schmidinger, M.; Tannir, N. M.; Powles, T.; Escudier, B. J.; Donskov, F.; Grünwald, V.; Sternberg, C. N.; Schoffski, P.; Szczylik, C.; Peltola, K. J.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Bergmann, L.; Donskov, F.; Motzer, R. J.; Voog, E.; Hovey, E. J.; Grüllich, C.; Nott, L. M.; Cuff, K. E.; Gil, T.; Jensen, N. V.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Grüllich, C.; Powles, T.; Motzer, R. J.; George, D. J.; Jonasch, E.; Pal, S. K.; Tannir, N. M.; Signoretti, S.; Mai, T. H.; Scheffold, C.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial
    Meeting Abstract

    Grnüwald, V.; Cella, D.; Escudier, B. J.; Hammers, H. J.; George, S.; Nathan, P.; Grimm, M. O.; Rini, B. I.; Doan, J.; Ivanescu, C.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Grüllich, C.; Motzer, R. J.; Powles, T.; Atkins, M.; Escudier, B. J.; McDermott, D.; Suarez, C.; Bracarda, S.; Stadler, W.; Donskov, F.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save